The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.